V₂ receptor antagonism with tolvaptan in heart failure

Bibliography

• ROSAMOND W, FLEGAL K, FRIDAY G et al.: Heart disease and stroke statistics – 2007 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation (2007) 115(5):E69-E171.
   PubMed Web of Science ®Google Scholar
• HILLEGE HL, GIRBES AR, DE KAM PJ et al.: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circualtion (2000) 102(2):203-210.
   PubMed Web of Science ®Google Scholar
• HILLEGE HL, NITSCH D, PFEFFER MA et al.: Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 113(5):671-678.
   PubMed Web of Science ®Google Scholar
• SMILDE TD, VAN VELDHUISEN DJ, NAVIS G et al.: Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation (2006) 114(15):1572-1580.
   PubMed Web of Science ®Google Scholar
• COOPER HA, DRIES DL, DAVIS CE et al.: Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation (1999) 100(12):1311-1315.
   PubMed Web of Science ®Google Scholar
• DRIES DL, EXNER DV, DOMANSKI MJ et al.: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J. Am. Coll. Cardiol. (2000) 35(3):681-689.
   PubMed Web of Science ®Google Scholar
• GHEORGHIADE M, NIAZI I, OUYANG J et al.: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 107(21):2690-2696.
   PubMed Web of Science ®Google Scholar
• GHEORGHIADE M, GATTIS WA, O'CONNOR CM et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA (2004) 291(16):1963-1971.
   PubMed Web of Science ®Google Scholar
• GHEORGHIADE M, KONSTAM MA, BURNETT JC Jr et al.: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA (2007) 297(12):1332-1343.
   PubMed Web of Science ®Google Scholar
• KONSTAM MA, GHEORGHIADE M, BURNETT JC Jr et al.: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA (2007) 297(12):1319-1331.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SS, BRATER DC, THOMAS I et al.: BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation (2002) 105(11):1348-1353.
   PubMed Web of Science ®Google Scholar
• PUBLICATION COMMITTEE FOR THE VMAC INVESTIGATORS (VASODILATATION IN THE MANAGEMENT OF ACUTE CHF): Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA (2002) 287(12):1531-1540.
   PubMed Web of Science ®Google Scholar
• COSTANZO MR, GUGLIN ME, SALTZBERG MT et al.: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. (2007) 49(6):675-683.
   PubMed Web of Science ®Google Scholar
• BIRNBAUMER M: Vasopressin receptors. Trends Endocrinol. Metab. (2000) 11(10):406-410.
   PubMed Web of Science ®Google Scholar
• NIELSEN S, FROKIAER J, MARPLES D et al.: Aquaporins in the kidney: from molecules to medicine. Physiol. Rev. (2002) 82(1):205-244.
   PubMed Web of Science ®Google Scholar
• WANG BC, GINTER GF, GOETZ KL: Augmented pressor response to vasopressin in awake dogs after cardiac denervation. Am. J. Physiol. (1987) 252(1 Part 2):R145-R152.
   PubMed Web of Science ®Google Scholar
• TERANISHI Y, SUGINO H, OZONO R et al.: Contribution of endogenous vasopressin to regional hemodynamics in borderline-hypertensive Hiroshima rats. Hypertens. Res. (2002) 25(2):241-248.
   PubMed Web of Science ®Google Scholar
• YAMAMURA Y, NAKAMURA S, ITOH S et al.: OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. (1998) 287(3):860-867.
   PubMed Web of Science ®Google Scholar
• HIRANO T, YAMAMURA Y, NAKAMURA S et al.: Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J. Pharmacol. Exp. Ther. (2000) 292(1):288-294.
   PubMed Web of Science ®Google Scholar
• COSTELLO-BOERRIGTER LC, SMITH WB, BOERRIGTER G et al.: Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol. (2006) 290(2):F273-F278.
   PubMed Web of Science ®Google Scholar
• HAUPTMAN PJ, ZIMMER C, UDELSON J et al.: Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J. Cardiovasc. Pharmacol. (2005) 46(5):609-614.
   PubMed Web of Science ®Google Scholar
• RANGASETTY UC, GHEORGHIADE M, URETSKY BF et al.: Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. Expert Opin. Investig. Drugs (2006) 15(5):533-540.
   PubMed Web of Science ®Google Scholar
• SHOAF SE, ELIZARI MV, WANG Z et al.: Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J. Cardiovasc. Pharmacol. Ther. (2005) 10(3):165-171.
   PubMed Web of Science ®Google Scholar
• SHOAF SE, WANG Z, MALLIKAARJUN S et al.: Lack of clinically significant interaction between steady date tolvaptan and digoxin in healthy volunteers. Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, Washington, DC, USA, (2 – 5 April 2003):PI-129.
   Google Scholar
• WANG Z, SHOAF SE, KUMARA S et al.: Lack of effect of tolvaptan on pharmacokinetics (PK) and pharmacodynamics (PD) of warfarin. Annual Meeting of American Society for Clinical Pharmacology and Therapeeutics, Washington, DC, USA, 2 – 5 April (2003):PII-60.
   Google Scholar
• NICCO C, WITTNER M, DISTEFANO A et al.: Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung. Hypertension (2001) 38(5):1143-1149.
   PubMed Web of Science ®Google Scholar
• BANKIR L, FERNANDES S, BARDOUX P et al.: Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J. Am. Soc. Nephrol. (2005) 16(7):1920-1928.
   PubMed Web of Science ®Google Scholar
• UDELSON JE, MCGREW FA, FLORES E et al.: Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J. Am. Coll. Cardiol. (2007) 49(22):2151-2159.
   PubMed Web of Science ®Google Scholar
• SCHRIER RW, GROSS P, GHEORGHIADE M et al.: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. (2006) 355(20):2099-2112.
   PubMed Web of Science ®Google Scholar
• UDELSON JE, SMITH WB, HENDRIX GH et al.: Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation (2001) 104(20):2417-2423.
   PubMed Web of Science ®Google Scholar
• GHALI JK, KOREN MJ, TAYLOR JR et al.: Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab. (2006) 91(6):2145-2152.
   PubMed Web of Science ®Google Scholar